These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22649281)

  • 1. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations.
    Sugimoto M; Furuta T
    Clin Exp Gastroenterol; 2012; 5():49-59. PubMed ID: 22649281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.
    McKeage K; Blick SK; Croxtall JD; Lyseng-Williamson KA; Keating GM
    Drugs; 2008; 68(11):1571-607. PubMed ID: 18627213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of esomeprazole in the treatment of acid disorders.
    Johnson DA
    Expert Opin Pharmacother; 2003 Feb; 4(2):253-64. PubMed ID: 12562316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esomeprazole for acid peptic disorders.
    Kale-Pradhan PB; Landry HK; Sypula WT
    Ann Pharmacother; 2002 Apr; 36(4):655-63. PubMed ID: 11918517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
    Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
    Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
    Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP; Wu TS; Dan YY
    J Clin Pharm Ther; 2015 Aug; 40(4):368-75. PubMed ID: 25893507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
    Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
    Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
    Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
    World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esomeprazole: a clinical review.
    Johnson TJ; Hedge DD
    Am J Health Syst Pharm; 2002 Jul; 59(14):1333-9. PubMed ID: 12132559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esomeprazole magnesium (Nexium).
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
    Nagase M; Shimada H; Nii M; Ueda S; Higashimori M; Ichikawa K; Zhang L; Zhou L; Chen Y; Zhou D; Dunyak J; Al-Huniti N
    J Clin Pharm Ther; 2020 Oct; 45(5):1030-1038. PubMed ID: 32227647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esomeprazole: A significant advance beyond omeprazole in the treatment of acid-related disease.
    Rabasseda X; Cole P
    Drugs Today (Barc); 2001 Nov; 37(11):767-781. PubMed ID: 12738973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of esomeprazole in patients with acid-peptic disorders.
    Beck J
    Gastroenterol Nurs; 2004; 27(2):44-9. PubMed ID: 15082946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.